Table 2 Persistence, adherence, and compliance stratified by age, gender, baseline EDSS score, and participation in BETAPLUS programme
Week 4 | Week 12 | Week 24 | ||||
|---|---|---|---|---|---|---|
Number of persistent patients (%) | ||||||
Total (FAS, N = 143) | 90.2 | 86.0 | 74.8 | |||
Age | ||||||
< 40 (N = 69) | 89.9 | 84.1 | 69.6 | |||
≥ 40 (N = 74) | 90.5 | 87.8 | 79.7 | |||
Gender | ||||||
Female (N = 99) | 90.9 | 83.8 | 73.7 | |||
Male (N = 44) | 88.6 | 90.9 | 77.3 | |||
EDSS baseline score | ||||||
< 3 (N = 90) | 92.2 | 90 | 78.9 | |||
≥ 3 (N = 34) | 91.2 | 85.3 | 67.7 | |||
Previous treatment with IFN beta-1b | ||||||
Yes (N = 106) | 89.6 | 84.0 | 70.8 | |||
No (N = 37) | 91.9 | 91.9 | 86.5 | |||
BETAPLUS participation | ||||||
Yes (N = 87) | 87.4 | 81.6 | 70.1 | |||
No (N = 56) | 94.6 | 92.9 | 82.1 | |||
Number of adherent patients (%) among all patients with at least one data readout from Betaconnect | ||||||
Total (N = 107) | 72.0 | 67.3 | 58.0 | |||
Age | ||||||
< 40 (N = 46) | 71.7 | 65.2 | 56.5 | |||
≥ 40 (N = 61) | 72.1 | 68. | 59.0 | |||
Gender | ||||||
Female (N = 75) | 74.7 | 66.7 | 57.3 | |||
Male (N = 32) | 65.6 | 68.8 | 59.4 | |||
EDSS baseline score | ||||||
< 3 (N = 67) | 76.1 | 71.6 | 58.2 | |||
≥ 3 (N = 27) | 63.0 | 55.6 | 55.6 | |||
Previous treatment with IFN beta-1b | ||||||
Yes (N = 75) | 68.0 | 62.7 | 49.3 | |||
No (N = 32) | 81.3 | 78.1 | 78.1 | |||
BETAPLUS participation | ||||||
Yes (N = 69) | 76.8 | 69.6 | 59.4 | |||
No (N = 38) | 63.2 | 63.2 | 55.3 | |||
Number of adherent patients (%) among all patients with data from corresponding visit | ||||||
N | % | N | % | N | % | |
Total | 95 | 81.1 | 83 | 86.8 | 77 | 80.5 |
Age | ||||||
< 40 years | 40 | 82.5 | 34 | 88.2 | 30 | 86.7 |
≥ 40 | 55 | 80 | 49 | 85.7 | 47 | 76.6 |
Gender | ||||||
Female | 66 | 84.9 | 57 | 87.7 | 53 | 81.1 |
Male | 29 | 72.4 | 26 | 84.6 | 24 | 79.2 |
EDSS baseline score | ||||||
< 3 | 59 | 86.4 | 54 | 88.9 | 47 | 83.0 |
≥ 3 | 24 | 70.8 | 18 | 83.33 | 19 | 79.0 |
Previous treatment with IFN beta-1b | ||||||
Yes | 66 | 77.3 | 56 | 83.9 | 50 | 74.0 |
No | 29 | 89.7 | 27 | 92.6 | 27 | 92.6 |
BETAPLUS participation | ||||||
Yes | 61 | 86.9 | 53 | 90.6 | 49 | 83.7 |
No | 34 | 70.6 | 30 | 80.0 | 28 | 75.0 |
Mean compliance (%) among all patients with data from corresponding visit | ||||||
Total | 95 | 86.3 | 83 | 91.9 | 77 | 92.9 |
Age | ||||||
< 40 years | 40 | 87.1 | 34 | 93.2 | 30 | 94.8 |
≥ 40 | 55 | 85.2 | 49 | 91.0 | 47 | 91.6 |
Gender | ||||||
Female | 66 | 88.8 | 57 | 91.5 | 53 | 93.47 |
Male | 29 | 80.7 | 26 | 92.8 | 24 | 91.6 |
EDSS baseline score | ||||||
< 3 | 59 | 89.72 | 54 | 93.5 | 47 | 94.9 |
≥ 3 | 24 | 79.4 | 18 | 89.4 | 19 | 90.4 |
Previous treatment with IFN beta-1b | ||||||
Yes | 66 | 84.5 | 56 | 91.1 | 50 | 90.2 |
No | 29 | 90.4 | 27 | 93.4 | 27 | 97.8 |
BETAPLUS participation | ||||||
Yes | 61 | 91.2 | 53 | 93.4 | 49 | 93.9 |
No | 34 | 77.6 | 30 | 89.1 | 28 | 91.0 |